Delivery Order SPE2DR25D2106-SPE2DR26F1GGF
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $61,117.01 by the Defense Logistics Agency on January 12, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The ultimate completion date is set for January 13, 2026. This delivery order is executed under...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $16,340.28 by the Defense Logistics Agency on August 4, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract represents a firm fixed-price delivery order with no set-aside designation and is scheduled for completion by August 5, 2025. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,349.17 by the Defense Logistics Agency on September 9, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract is not set-aside and was competitively awarded with a firm fixed price structure and an ultimate completion date of September 10, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $11,772.16 firm fixed-price delivery order for Repatha 140 mg/ml SureClick auto-injectors on January 13, 2026, with an ultimate completion date of January 14, 2026. The Defense Logistics Agency funded this award, which carries no set-aside designation, indicating it was competitively awarded. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on November 26, 2025, by the Defense Logistics Agency for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order has a ceiling value of $3,750.79 and an ultimate completion date of November 28, 2025. The contract is not set-aside and represents a competitive award under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,616.16 by the Defense Logistics Agency on September 16, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injector medication. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 17, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for $72,275.29 to supply Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by December 3, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract action under AmerisourceBergen's larger DLA Troop Support Medical Indefinite Delivery Contract (IDC),...
- The Defense Logistics Agency awarded a $15,882.49 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of December 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $13,542.27 for Repatha 140 mg/ml SureClick auto-injectors by the Defense Logistics Agency on November 18, 2025, with an ultimate completion date of November 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $29,995.79 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 11, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, reflecting...
- SPE2DR25D2106Indefinite Delivery Contract
- SPE2DR25D2106-SPE2DR26F1GGFDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,971.95 firm fixed-price delivery order from the Defense Logistics Agency on January 15, 2026, for Repatha 140 mg/ml SureClick auto-injectors. The award is unset-aside and competitively awarded, with an ultimate completion date of January 16, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare programs globally. The Defense Logistics Agency utilizes this expansive IDC to procure a wide range of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Repatha is a PCSK9 inhibitor used for cholesterol management in cardiovascular disease treatment, reflecting DLA's ongoing procurement of critical medications for military healthcare systems and veteran support programs. AmerisourceBergen's demonstrated capability to fulfill federal medical supply requirements through open competition, combined with its extensive portfolio of pharmaceutical deliveries, positions the company as a key supplier within the Defense Health Agency's medical supply chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 1/14/26 |